VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma
March 25, 2015 at 07:01 AM EDT
VBL Therapeutics (Nasdaq: VBLT), a late-stage clinical biotechnology company focused on the discovery, development and ...